Your browser doesn't support javascript.
loading
Adalimumab-Induced Lupus Serositis: A Case Report and Review of the Literature.
Lee, Sandy; Lafian, Anna; Mahani, Tandis; Hojjati, Mehrnaz.
Afiliación
  • Lee S; Department of Rheumatology, Keck School of Medicine of the University of Southern California, Los Angeles, USA.
  • Lafian A; Division of Rheumatology, Department of Internal Medicine, Loma Linda University School of Medicine, Loma Linda, USA.
  • Mahani T; Department of Internal Medicine, University of California, Riverside, USA.
  • Hojjati M; Division of Rheumatology, Department of Internal Medicine, Loma Linda University School of Medicine, Loma Linda, USA.
Cureus ; 15(2): e34568, 2023 Feb.
Article en En | MEDLINE | ID: mdl-36874325
ABSTRACT
Tumor necrosis factor-alpha (TNF-alpha) antagonist use is prevalent for the treatment of autoimmune diseases, including psoriasis, ankylosing spondylitis, and rheumatoid arthritis. Since the onset of its use over the last couple of decades, there have been increasing reports of drug-induced antibodies and antitumor necrosis factor-alpha-induced lupus (ATIL). Herein, we present a case of pericarditis induced by tumor necrosis factor-alpha antagonist, adalimumab. A 61-year-old male with psoriatic arthritis treated with adalimumab injections for five years presented with dyspnea, chest tightness, and three-pillow orthopnea. Echocardiogram showed moderate pericardial effusion with early signs of tamponade. Adalimumab was discontinued. He was started on colchicine and steroids for a high suspicion of drug-induced serositis. With the increased use of tumor necrosis factor-alpha antagonists, adverse reactions such as ATIL will become more common. Such cases need to be reported to spread awareness of this possible complication and avoid any delay in treatment and care.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Cureus Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Cureus Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos